OncoMatch/Clinical Trials/NCT07182279
Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
Is NCT07182279 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Brachytherapy for prostate cancer (adenocarcinoma).
Treatment: Brachytherapy — This is a Phase I/II trial evaluating the effectiveness of adding neoadjuvant HDR-B prior to RALP for HR-PCa patients with selective AAB for decipher high risk or pathologically node positive patients. Patients with newly diagnosed, histologically confirmed, non-metastatic, HR-PCa who are scheduled to receive RALP will be eligible to participate in the study.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage T2C, ≥T3A (AJCC 8th Edition)
Clinical or radiographic stage ≥T3a per AJCC (American Joint Committee on Cancer) 8th Edition Staging Manual and/or At least two out of four of the following: ... clinical stage = T2b/T2c
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: androgen deprivation therapy
Exception: finasteride if discontinued > 3 months prior to enrollment
No prior androgen deprivation therapy in the past 6 months. History of androgen deprivation therapy within the past 6 months (except finasteride if discontinued > 3 mo. prior to enrollment).
Cannot have received: pelvic radiation therapy
History of prior pelvic radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Houston Methodist · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify